Payment overview · 2025
General Payments
$282.96
3 reported records · 3 companies
Healthcare provider profile · identity verified
Jack F Scheuer, MD
Allopathic & Osteopathic Physicians|Internal Medicine · CAMDEN, SC · NPI 1871544403
Verified facts
What the public records show
CMS Open Payments records show Jack F Scheuer, MD received $282.96 in general payments during 2025 across 3 reported records.
Davol Inc. accounted for 41.6% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 3 associated products.
A separate comparison found the same explicitly named product in public Medicare Part D data: Ozempic.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported FARXIGA as an associated drug or biological on 106133 records involving 42906 distinct recipient NPIs. Public Medicare Part D data also shows 18 claims for Farxiga by this doctor in 2024.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported SYMBICORT as an associated drug or biological on 71 records involving 51 distinct recipient NPIs. Public Medicare Part D data also shows 34 claims for Symbicort by this doctor in 2024.
Novo Nordisk Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Ozempic as an associated drug or biological on 261625 records involving 77793 distinct recipient NPIs. Public Medicare Part D data also shows 70 claims for Ozempic by this doctor in 2024.
Novo Nordisk Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Rybelsus as an associated drug or biological on 161257 records involving 55409 distinct recipient NPIs. Public Medicare Part D data also shows 12 claims for Rybelsus by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| Davol Inc. | Unresolved — no canonical attribution shown | $117.71 | 41.6% | 1 | 2025 |
| Novo Nordisk Inc | Unresolved — no canonical attribution shown | $102.24 | 36.1% | 1 | 2025 |
| AstraZeneca Pharmaceuticals LP | Unresolved — no canonical attribution shown | $63.01 | 22.3% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $282.96 | 3 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| Phasix Mesh Normalized: phasix mesh |
Device | Davol Inc. | $117.71 | 1 | 2025 |
Source payment records
|
|||||
| Ozempic Normalized: ozempic |
Drug | Novo Nordisk Inc | $102.24 | 1 | 2025 |
Source payment records
|
|||||
| AIRSUPRA Normalized: airsupra |
Drug | AstraZeneca Pharmaceuticals LP | $63.01 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
| Open Payments product | Payment year | Part D brand | Part D year | Claims | Match method | Source |
|---|---|---|---|---|---|---|
| Ozempic ozempic |
2025 | Ozempic | 2024 | 70 | exact normalized | Medicare Part D |
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | FARXIGA open payments reported associated product |
CMS Open Payments — General Payments 106133 supporting records · 42906 recipient NPIs · example record 1206131362 |
Farxiga · 2024 Exact normalized brand match · 1 Part D row |
18 | suppressed by CMS |
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | SYMBICORT open payments reported associated product |
CMS Open Payments — General Payments 71 supporting records · 51 recipient NPIs · example record 1206132610 |
Symbicort · 2024 Exact normalized brand match · 1 Part D row |
34 | suppressed by CMS |
| Novo Nordisk Inc Exact reporting entity; no affiliate inference |
2025 | Ozempic open payments reported associated product |
CMS Open Payments — General Payments 261625 supporting records · 77793 recipient NPIs · example record 1188130076 |
Ozempic · 2024 Exact normalized brand match · 1 Part D row |
70 | 20 |
| Novo Nordisk Inc Exact reporting entity; no affiliate inference |
2025 | Rybelsus open payments reported associated product |
CMS Open Payments — General Payments 161257 supporting records · 55409 recipient NPIs · example record 1188130076 |
Rybelsus · 2024 Exact normalized brand match · 1 Part D row |
12 | suppressed by CMS |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Atorvastatin Calcium | Atorvastatin Calcium | 777 | 207 |
| Amlodipine Besylate | Amlodipine Besylate | 711 | 176 |
| Levothyroxine Sodium | Levothyroxine Sodium | 487 | 131 |
| Olmesartan Medoxomil | Olmesartan Medoxomil | 402 | 96 |
| Metoprolol Succinate | Metoprolol Succinate | 303 | 79 |
| Omeprazole | Omeprazole | 292 | 94 |
| Metformin Hcl | Metformin Hcl | 287 | 89 |
| Lisinopril | Lisinopril | 284 | 83 |
| Eliquis | Apixaban | 281 | 49 |
| Furosemide | Furosemide | 278 | 76 |
| Pantoprazole Sodium | Pantoprazole Sodium | 276 | 71 |
| Rosuvastatin Calcium | Rosuvastatin Calcium | 276 | 80 |
| Gabapentin | Gabapentin | 267 | 68 |
| Jardiance | Empagliflozin | 255 | 57 |
| Meloxicam | Meloxicam | 230 | 66 |
| Allopurinol | Allopurinol | 222 | 51 |
| Losartan Potassium | Losartan Potassium | 203 | 55 |
| Tamsulosin Hcl | Tamsulosin Hcl | 188 | 63 |
| Metoprolol Tartrate | Metoprolol Tartrate | 182 | 53 |
| Hydrochlorothiazide | Hydrochlorothiazide | 170 | 50 |
| Simvastatin | Simvastatin | 169 | 45 |
| Zolpidem Tartrate | Zolpidem Tartrate | 168 | 25 |
| Hydrocodone-Acetaminophen | Hydrocodone/Acetaminophen | 167 | 46 |
| Escitalopram Oxalate | Escitalopram Oxalate | 164 | 43 |
| Glimepiride | Glimepiride | 164 | 45 |
| Pravastatin Sodium | Pravastatin Sodium | 148 | 41 |
| Trazodone Hcl | Trazodone Hcl | 147 | 42 |
| Lorazepam | Lorazepam | 140 | 32 |
| Tramadol Hcl | Tramadol Hcl | 136 | 53 |
| Potassium Chloride | Potassium Chloride | 135 | 47 |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 127 | 40 |
| Alprazolam | Alprazolam | 125 | 33 |
| Clopidogrel | Clopidogrel Bisulfate | 114 | 33 |
| Carvedilol | Carvedilol | 113 | 30 |
| Metformin Hcl Er | Metformin Hcl | 110 | 28 |
| Montelukast Sodium | Montelukast Sodium | 103 | 26 |
| Fluticasone Propionate | Fluticasone Propionate | 99 | 30 |
| Tizanidine Hcl | Tizanidine Hcl | 93 | 36 |
| Donepezil Hcl | Donepezil Hcl | 91 | 28 |
| Spironolactone | Spironolactone | 91 | 27 |
| Sertraline Hcl | Sertraline Hcl | 86 | 21 |
| Mirtazapine | Mirtazapine | 75 | 15 |
| Vitamin D2 | Ergocalciferol (Vitamin D2) | 74 | 18 |
| Finasteride | Finasteride | 70 | 17 |
| Ozempic | Semaglutide | 70 | 20 |
| Cephalexin | Cephalexin | 69 | 51 |
| Valsartan-Hydrochlorothiazide | Valsartan/Hydrochlorothiazide | 66 | 21 |
| Diazepam | Diazepam | 63 | suppressed |
| Fenofibrate | Fenofibrate | 63 | 15 |
| Azithromycin | Azithromycin | 61 | 50 |
| Duloxetine Hcl | Duloxetine Hcl | 61 | 12 |
| Soliqua 100-33 | Insulin Glargine/Lixisenatide | 61 | 14 |
| Famotidine | Famotidine | 57 | 18 |
| Isosorbide Mononitrate Er | Isosorbide Mononitrate | 57 | 17 |
| Quetiapine Fumarate | Quetiapine Fumarate | 57 | 11 |
| Buspirone Hcl | Buspirone Hcl | 56 | 17 |
| Amlodipine Besylate-Benazepril | Amlodipine Besylate/Benazepril | 55 | 17 |
| Bupropion Xl | Bupropion Hcl | 55 | suppressed |
| Valsartan | Valsartan | 54 | 18 |
| Clonazepam | Clonazepam | 53 | 18 |
| Lisinopril-Hydrochlorothiazide | Lisinopril/Hydrochlorothiazide | 53 | 16 |
| Cyclobenzaprine Hcl | Cyclobenzaprine Hcl | 52 | 15 |
| Esomeprazole Magnesium | Esomeprazole Magnesium | 51 | 17 |
| Torsemide | Torsemide | 51 | 16 |
| Fluoxetine Hcl | Fluoxetine Hcl | 49 | suppressed |
| Irbesartan | Irbesartan | 48 | 14 |
| Citalopram Hbr | Citalopram Hydrobromide | 47 | 14 |
| Amiodarone Hcl | Amiodarone Hcl | 46 | suppressed |
| Amitriptyline Hcl | Amitriptyline Hcl | 46 | 12 |
| Entresto | Sacubitril/Valsartan | 46 | 15 |
| Ezetimibe | Ezetimibe | 44 | 17 |
| Roflumilast | Roflumilast | 44 | suppressed |
| Dicyclomine Hcl | Dicyclomine Hcl | 43 | 13 |
| Clotrimazole-Betamethasone | Clotrimazole/Betamethasone Dip | 41 | 20 |
| Meclizine Hcl | Meclizine Hcl | 40 | 16 |
| Amoxicillin-Clavulanate Potass | Amoxicillin/Potassium Clav | 39 | 34 |
| Labetalol Hcl | Labetalol Hcl | 38 | suppressed |
| Ropinirole Hcl | Ropinirole Hcl | 38 | suppressed |
| Alendronate Sodium | Alendronate Sodium | 37 | 14 |
| Glipizide | Glipizide | 37 | suppressed |
| Mupirocin | Mupirocin | 37 | 21 |
| Synthroid | Levothyroxine Sodium | 36 | suppressed |
| Atenolol | Atenolol | 35 | 12 |
| Levetiracetam | Levetiracetam | 35 | 13 |
| Chlorthalidone | Chlorthalidone | 34 | 11 |
| Clonidine Hcl | Clonidine Hcl | 34 | suppressed |
| Diclofenac Sodium | Diclofenac Sodium | 34 | suppressed |
| Oxybutynin Chloride | Oxybutynin Chloride | 34 | 14 |
| Pioglitazone Hcl | Pioglitazone Hcl | 34 | 12 |
| Symbicort | Budesonide/Formoterol Fumarate | 34 | suppressed |
| Lansoprazole | Lansoprazole | 33 | suppressed |
| Memantine Hcl | Memantine Hcl | 33 | suppressed |
| Venlafaxine Hcl Er | Venlafaxine Hcl | 33 | suppressed |
| Benazepril Hcl | Benazepril Hcl | 32 | 11 |
| Diltiazem 24hr Er (Cd) | Diltiazem Hcl | 32 | 13 |
| Lantus Solostar | Insulin Glargine,hum.Rec.Anlog | 32 | suppressed |
| Trelegy Ellipta | Fluticasone/Umeclidin/Vilanter | 32 | 13 |
| Baclofen | Baclofen | 31 | suppressed |
| Micafungin | Micafungin Sodium | 30 | suppressed |
| Paroxetine Hcl | Paroxetine Hcl | 30 | suppressed |
| Primidone | Primidone | 30 | suppressed |
| Olmesartan-Hydrochlorothiazide | Olmesartan/Hydrochlorothiazide | 29 | suppressed |
| Topiramate | Topiramate | 29 | suppressed |
| Trulicity | Dulaglutide | 29 | suppressed |
| Doxazosin Mesylate | Doxazosin Mesylate | 28 | suppressed |
| Hydroxyzine Hcl | Hydroxyzine Hcl | 28 | suppressed |
| Sucralfate | Sucralfate | 28 | 11 |
| Xarelto | Rivaroxaban | 28 | suppressed |
| Janumet | Sitagliptin Phos/Metformin Hcl | 27 | suppressed |
| Januvia | Sitagliptin Phosphate | 27 | suppressed |
| Fenofibrate | Fenofibrate Nanocrystallized | 26 | suppressed |
| Ibuprofen | Ibuprofen | 26 | suppressed |
| Latanoprost | Latanoprost | 26 | suppressed |
| Ondansetron Hcl | Ondansetron Hcl | 26 | suppressed |
| Prednisone | Prednisone | 26 | 12 |
| Celecoxib | Celecoxib | 25 | suppressed |
| Warfarin Sodium | Warfarin Sodium | 25 | suppressed |
| Ciprofloxacin Hcl | Ciprofloxacin Hcl | 24 | 22 |
| Myrbetriq | Mirabegron | 24 | suppressed |
| Oxycodone-Acetaminophen | Oxycodone Hcl/Acetaminophen | 24 | suppressed |
| Memantine Hcl Er | Memantine Hcl | 23 | suppressed |
| Aripiprazole | Aripiprazole | 22 | suppressed |
| Nuedexta | Dextromethorphan Hbr/Quinidine | 22 | suppressed |
| Basaglar Kwikpen U-100 | Insulin Glargine,hum.Rec.Anlog | 21 | suppressed |
| Fluticasone-Salmeterol | Fluticasone Propion/Salmeterol | 21 | suppressed |
| Mometasone Furoate | Mometasone Furoate | 21 | suppressed |
| Hydralazine Hcl | Hydralazine Hcl | 20 | suppressed |
| Klor-Con M20 | Potassium Chloride | 20 | suppressed |
| Ondansetron Odt | Ondansetron | 20 | 14 |
| Anoro Ellipta | Umeclidinium Brm/Vilanterol Tr | 19 | suppressed |
| Edarbi | Azilsartan Medoxomil | 19 | suppressed |
| Losartan-Hydrochlorothiazide | Losartan/Hydrochlorothiazide | 19 | suppressed |
| Phenytoin Sodium Extended | Phenytoin Sodium Extended | 19 | suppressed |
| Sumatriptan Succinate | Sumatriptan Succinate | 19 | suppressed |
| Tradjenta | Linagliptin | 19 | suppressed |
| Farxiga | Dapagliflozin Propanediol | 18 | suppressed |
| Fluconazole | Fluconazole | 18 | 15 |
| Humalog Mix 75-25 Kwikpen | Insulin Lispro Protamin/Lispro | 18 | suppressed |
| Naproxen | Naproxen | 18 | suppressed |
| Triamterene-Hydrochlorothiazid | Triamterene/Hydrochlorothiazid | 18 | suppressed |
| Amlodipine-Valsartan | Amlodipine Besylate/Valsartan | 17 | suppressed |
| Dexlansoprazole Dr | Dexlansoprazole | 17 | suppressed |
| Metoclopramide Hcl | Metoclopramide Hcl | 17 | suppressed |
| Nano 2nd Gen Pen Needle | Pen Needle, Diabetic | 17 | suppressed |
| Pregabalin | Pregabalin | 17 | suppressed |
| Ventolin Hfa | Albuterol Sulfate | 17 | suppressed |
| Doxycycline Hyclate | Doxycycline Hyclate | 16 | 12 |
| Dropsafe Prep Pads | Alcohol Antiseptic Pads | 16 | suppressed |
| Estradiol | Estradiol | 16 | suppressed |
| Humalog Kwikpen U-100 | Insulin Lispro | 16 | suppressed |
| Promethazine Hcl | Promethazine Hcl | 16 | suppressed |
| Sildenafil Citrate | Sildenafil Citrate | 16 | suppressed |
| Triamcinolone Acetonide | Triamcinolone Acetonide | 16 | suppressed |
| Valacyclovir | Valacyclovir Hcl | 16 | suppressed |
| Colchicine | Colchicine | 15 | suppressed |
| Digoxin | Digoxin | 15 | suppressed |
| Glipizide Er | Glipizide | 15 | suppressed |
| Lantus | Insulin Glargine,hum.Rec.Anlog | 15 | suppressed |
| Methylphenidate Hcl | Methylphenidate Hcl | 15 | suppressed |
| Novolog Flexpen | Insulin Aspart | 15 | suppressed |
| Nystatin | Nystatin | 15 | suppressed |
| Cilostazol | Cilostazol | 14 | suppressed |
| Ketoconazole | Ketoconazole | 14 | suppressed |
| Midodrine Hcl | Midodrine Hcl | 14 | suppressed |
| Scopolamine | Scopolamine | 14 | suppressed |
| Bupropion Hcl Sr | Bupropion Hcl | 13 | suppressed |
| Bydureon Bcise | Exenatide Microspheres | 13 | suppressed |
| Daptomycin | Daptomycin | 13 | suppressed |
| Novolog Mix 70-30 Flexpen | Insulin Aspart Prot/Insuln Asp | 13 | suppressed |
| Oxcarbazepine | Oxcarbazepine | 13 | suppressed |
| Paxlovid | Nirmatrelvir/Ritonavir | 13 | 13 |
| Testosterone | Testosterone | 13 | suppressed |
| Tresiba Flextouch U-200 | Insulin Degludec | 13 | suppressed |
| Divalproex Sodium | Divalproex Sodium | 12 | suppressed |
| Isosorbide Dinit-Hydralazine | Isosorbide Dinit/Hydralazine | 12 | suppressed |
| Olanzapine | Olanzapine | 12 | suppressed |
| Pramipexole Dihydrochloride | Pramipexole Di-Hcl | 12 | suppressed |
| Repatha Sureclick | Evolocumab | 12 | suppressed |
| Rybelsus | Semaglutide | 12 | suppressed |
| Sulfamethoxazole-Trimethoprim | Sulfamethoxazole/Trimethoprim | 12 | suppressed |
| Telmisartan-Hydrochlorothiazid | Telmisartan/Hydrochlorothiazid | 12 | suppressed |
| Tivicay | Dolutegravir Sodium | 12 | suppressed |
| Venlafaxine Hcl | Venlafaxine Hcl | 12 | suppressed |
| Xifaxan | Rifaximin | 12 | suppressed |
| Acetaminophen-Codeine | Acetaminophen With Codeine | 11 | suppressed |
| Descovy | Emtricitabine/Tenofov Alafenam | 11 | suppressed |
| Icosapent Ethyl | Icosapent Ethyl | 11 | suppressed |
| Mounjaro | Tirzepatide | 11 | suppressed |
| Oxybutynin Chloride Er | Oxybutynin Chloride | 11 | suppressed |
| Paliperidone Er | Paliperidone | 11 | suppressed |
| Rabeprazole Sodium | Rabeprazole Sodium | 11 | suppressed |
| Shingrix | Varicella-Zoster Ge/As01b/Pf | 11 | suppressed |
| Tresiba Flextouch U-100 | Insulin Degludec | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $282.96 · 3 records | Davol Inc. | AIRSUPRA, Ozempic, Phasix Mesh | 4 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- What role, if any, does Ozempic play in your treatment recommendations for me?
- How do you evaluate evidence when you have a financial relationship with AstraZeneca Pharmaceuticals LP?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error